Stifel Nicolaus began coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $181.00 target price on the biopharmaceutical company’s stock.

GWPH has been the topic of a number of other research reports. Cantor Fitzgerald set a $192.00 price target on GW Pharmaceuticals PLC- and gave the company a buy rating in a report on Tuesday, April 17th. Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a hold rating to a strong-buy rating and set a $166.00 price target on the stock in a report on Wednesday, July 25th. Cowen restated a buy rating and set a $165.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, May 9th. ValuEngine upgraded GW Pharmaceuticals PLC- from a hold rating to a buy rating in a report on Wednesday, April 18th. Finally, BidaskClub upgraded GW Pharmaceuticals PLC- from a buy rating to a strong-buy rating in a report on Wednesday, May 30th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. GW Pharmaceuticals PLC- presently has an average rating of Buy and a consensus target price of $179.14.

GWPH opened at $136.06 on Tuesday. The stock has a market capitalization of $3.75 billion, a PE ratio of -19.58 and a beta of 2.55. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a 12 month low of $96.42 and a 12 month high of $164.76.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.40) by $1.14. The firm had revenue of $3.46 million for the quarter, compared to the consensus estimate of $2.00 million. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. analysts predict that GW Pharmaceuticals PLC- will post -9.02 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the stock. Verition Fund Management LLC purchased a new position in GW Pharmaceuticals PLC- during the 2nd quarter valued at about $322,000. Sio Capital Management LLC purchased a new position in GW Pharmaceuticals PLC- during the 2nd quarter valued at about $1,499,000. Flagship Harbor Advisors LLC purchased a new position in GW Pharmaceuticals PLC- during the 2nd quarter valued at about $109,000. Morgan Stanley increased its holdings in GW Pharmaceuticals PLC- by 9.8% during the 2nd quarter. Morgan Stanley now owns 378,776 shares of the biopharmaceutical company’s stock valued at $52,855,000 after purchasing an additional 33,784 shares during the period. Finally, Baker BROS. Advisors LP increased its holdings in GW Pharmaceuticals PLC- by 45.1% during the 2nd quarter. Baker BROS. Advisors LP now owns 321,800 shares of the biopharmaceutical company’s stock valued at $44,904,000 after purchasing an additional 100,000 shares during the period. Institutional investors own 73.80% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Read More: How to Invest in Marijuana Stocks

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.